Northwestern University · PharmacologyWatterson Neuropharmacology Lab
Daniel Martin Watterson · Evanston, Illinois
Research Focus
Dr. Daniel Watterson's lab at Northwestern University focuses on developing new treatments for Alzheimer's disease by repurposing existing drugs. The lab is currently working on a drug called MW189, which has shown promise in reducing inflammation in the brain, a key factor in Alzheimer's progression. Through their research, they aim to streamline the process of bringing this drug to clinical trials, ultimately helping patients with dementia and related disorders.
Alzheimer's DiseaseCNS Drug DevelopmentDrug RepurposingCytokine DysregulationNeurodegeneration
Research Aims
3AIM 01Produce GMP quality oral drug formulation
AIM 02Conduct extended toxicity studies in animals
AIM 03Prepare for phase 2 clinical trials for Alzheimer's patients
Skills the Lab Values
GMP Drug ProductionToxicology StudiesClinical Trial PreparationPharmacokinetics AssessmentCytokine Analysis
Output against the department
Publications267top 30% of dept.138th of 462
this lab
most publishedleast published
Citations11ktop 35% of dept.160th of 462
this lab
most citedleast cited
Career totals from OpenAlex, compared against labs that share a department. A department spans everything from one paper to tens of thousands, so bar heights are on a log scale — otherwise the largest lab would flatten every other bar to a line.